DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)

NCT ID: NCT05010369

Last Updated: 2025-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-02

Study Completion Date

2025-06-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lymphoma diagnosis often involves removal and biopsy of one or more lymph nodes. Many (around half) of these diagnostic procedures show that no cancer is present, hence unnecessary removal results in numerous side effects and complications. The procedure is also highly invasive.

The investigators have already shown that it is possible to tell the difference between healthy and diseased tissue in the laboratory by looking at the light emitted by tissue when a low power laser is shone on to it. The investigators intend to use this technique, known as "Raman Spectroscopy" (RS) to tell if tissue in the node is cancerous or healthy. By combining RS with a fine needle, the technique can target tissues below the skin with minimal invasion. Our needle will provide the clinician with instant diagnosis without the delay and cost of a laboratory analysis by pathologists.

The investigators have designed a probe that slides through a fine needle, guided by ultrasound, to the lymph node. The space between the two needles provides space for cell aspirate.

The investigators propose to measure spectra from excess lymph node biopsy samples taken during standard routine diagnostic biopsy.

The investigators are also interested to see if they can successfully extract a fine needle aspiration (FNA) biopsy sample using the device, as well as record a RS measurement. If successful this would ease clinical adoption as the study could run in parallel with existing standard routine clinical practice, using just one device.

This study will evaluate the new device on half a lymph node that will be excised and snap-frozen during a routine surgical biopsy, to gather data for submission of approvals for an in-vivo study to follow.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Surplus lymph node tissue collected from patients undergoing routine surgical treatment for head \& neck disease will be investigated using vibrational spectroscopy.

The project will develop a combined FNA/Raman spectroscopy needle probe. This study will evaluate this device on excised lymph node tissue to gather data for submission of approvals for an in-vivo study to follow. Raman \& FTIR (fourier transform infrared) spectra will be correlated with routine histopathology results using multivariate analysis methods. Cytology samples taken using the device will be compared with histopathology results.

Aims

To demonstrate that the FNA/Raman spectroscopy probe device, developed as part of this project, can:

Safely perform measurement of Raman spectra on excised lymph node tissue Safely perform FNA (fine needle aspiration) biopsies on excised lymph node tissue To evaluate the performance of a Raman needle probe to detect lymphoma \& malignancy in excised head \& neck lymph nodes and differentiate from benign nodes.

To develop the investigators understanding of vibrational spectroscopy signal characteristics in head \& neck lymph nodes (through Raman \& FTIR mapping measurements of tissue sections).

Objectives To test a new combined FNA and spectroscopic device on ex vivo tissue in preparation for an in vivo study.

Outcome

Primary Outcome Measures The FNA/Raman spectroscopy probe device can be used safely on excised lymph nodes to measure tissue spectra and collect FNA biopsies.

Diagnostic performance of vibrational spectroscopy for differentiation of lymphoma \& malignant nodes from benign nodes.

Secondary Outcome Measures Evaluation of the performance of a Raman needle probe to detect lymphoma \& malignancy in excised head \& neck lymph nodes and differentiate from benign nodes. To develop the investigators understanding of vibrational spectroscopy signal characteristics in head \& neck lymph nodes (through Raman \& FTIR mapping measurements of tissue sections).

Evaluation of the performance of a Raman needle probe to measure head \& neck lymph nodes (ergonomic design, ease of use etc.).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

non-hodgkin lymphoma

patients diagnosed with non-hodgkin lymphoma

Group Type EXPERIMENTAL

spectroscopic measurement

Intervention Type DIAGNOSTIC_TEST

measurement of the tissue with spectroscopy

FNA biopsy

Intervention Type DIAGNOSTIC_TEST

a fine needle aspiration (FNA) biopsy will be taken

histopathology and cytology

Intervention Type DIAGNOSTIC_TEST

Histopathology and cytology will be performed on the samples

hodgkin lymphoma

patients diagnosed with hodgkin lymphoma

Group Type EXPERIMENTAL

spectroscopic measurement

Intervention Type DIAGNOSTIC_TEST

measurement of the tissue with spectroscopy

FNA biopsy

Intervention Type DIAGNOSTIC_TEST

a fine needle aspiration (FNA) biopsy will be taken

histopathology and cytology

Intervention Type DIAGNOSTIC_TEST

Histopathology and cytology will be performed on the samples

squamous cell carcinoma

patients diagnosed with squamous cell carcinoma

Group Type EXPERIMENTAL

spectroscopic measurement

Intervention Type DIAGNOSTIC_TEST

measurement of the tissue with spectroscopy

FNA biopsy

Intervention Type DIAGNOSTIC_TEST

a fine needle aspiration (FNA) biopsy will be taken

histopathology and cytology

Intervention Type DIAGNOSTIC_TEST

Histopathology and cytology will be performed on the samples

reactive

patients diagnosed with a reactive (non-cancerous) lymph node

Group Type EXPERIMENTAL

spectroscopic measurement

Intervention Type DIAGNOSTIC_TEST

measurement of the tissue with spectroscopy

FNA biopsy

Intervention Type DIAGNOSTIC_TEST

a fine needle aspiration (FNA) biopsy will be taken

histopathology and cytology

Intervention Type DIAGNOSTIC_TEST

Histopathology and cytology will be performed on the samples

other

none of the above. Other cancer and non-cancer conditions

Group Type EXPERIMENTAL

spectroscopic measurement

Intervention Type DIAGNOSTIC_TEST

measurement of the tissue with spectroscopy

FNA biopsy

Intervention Type DIAGNOSTIC_TEST

a fine needle aspiration (FNA) biopsy will be taken

histopathology and cytology

Intervention Type DIAGNOSTIC_TEST

Histopathology and cytology will be performed on the samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

spectroscopic measurement

measurement of the tissue with spectroscopy

Intervention Type DIAGNOSTIC_TEST

FNA biopsy

a fine needle aspiration (FNA) biopsy will be taken

Intervention Type DIAGNOSTIC_TEST

histopathology and cytology

Histopathology and cytology will be performed on the samples

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

raman infra red fine needle aspiration biopsy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing biopsy or excision of more than one lymph node as part of their routine clinical care within Gloucestershire Hospitals NHS Foundation Trust.
* Patients undergoing lymphadenectomy as part of routine treatment

Exclusion Criteria

* Patients requiring biopsy of only one lymph node
* Patients unable to consent to the study due to communication difficulties
* Patients unable to consent to the study due to lack of capacity
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gloucestershire Hospitals NHS Foundation Trust

OTHER

Sponsor Role collaborator

University of Bristol

OTHER

Sponsor Role collaborator

University of Exeter

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nick Stone

Role: PRINCIPAL_INVESTIGATOR

University of Exeter

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gloucestershire Hospitals NHS Foundation Trust

Gloucester, Gloucestershire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

272392

Identifier Type: REGISTRY

Identifier Source: secondary_id

II-LB-1117-20002

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

1819/31-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.